Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 14, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and

Todd M Morgan1, Lauren H Lenz2, Ivan Henriquez3

  • 1Division of Urologic Oncology, Rogel Cancer Center, University of Michigan, Ann Arbor, MI.

Clinical Genitourinary Cancer
|June 12, 2026
PubMed

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Personalized whole-genome-based ctDNA dynamics during neoadjuvant therapy across breast cancer subtypes: results from MONITOR-Breast.

Future oncology (London, England)·2026
Same author

Polygenic Risk Scores for Breast Cancer Among African American Women With High Risk.

JAMA network open·2026
Same author

Development and validation of a digital pathology artificial intelligence (DPAI)-derived risk score predicting Gleason grade group reclassification for patients who are candidates for active surveillance.

Future oncology (London, England)·2026
Same author

Reply to "Progress on Pharmacogenetic Tests for Antidepressant Drug Selection Requires Properly Designed Studies".

Journal of clinical psychopharmacology·2026
Same author

Beyond treatment volume: when pelvic radiotherapy may still matter in high-risk localised prostate cancer.

Frontiers in oncology·2026
Summary

The combined clinical risk (CCR) score, Prolaris, accurately predicts outcomes for localized prostate cancer patients. It provides valuable prognostic information beyond existing risk models, aiding treatment decisions.

Area of Science:

  • Oncology
  • Urology
  • Medical Informatics

Background:

  • Localized prostate cancer management involves risk stratification to guide treatment decisions.
  • Existing tools like NCCN guidelines and CAPRA scores aid in risk assessment.
  • There is a need for enhanced prognostic tools to personalize patient management.

Purpose of the Study:

  • To systematically review and synthesize evidence for the Prolaris combined clinical risk (CCR) score.
  • To evaluate CCR's utility as a decision-making tool in localized prostate cancer care.
  • To assess CCR's prognostic impact on patient outcomes across the care continuum.

Main Methods:

  • Systematic literature search and individual participant data (IPD) collection.
  • Two-step IPD analysis using Cox proportional hazards models.
Keywords:
MetastasisPrognosisProlarisProstate biopsyProstate cancer-specific mortality

Related Experiment Videos

Last Updated: Jun 14, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

  • Random-effects meta-analyses with Knapp-Hartung adjustment for hazard ratio estimation.

    • Main Results:

    • Fourteen studies with 8478 patients (7924 with IPD) were included.
    • CCR was prognostic for composite distant metastasis (DM) and prostate cancer-specific mortality (PCSM) (HR 2.28, P = 9.1 × 10⁻⁹).
    • CCR provided independent prognostic information beyond Gleason, CAPRA, and NCCN risk stratification (all P < 10⁻⁵).

    Conclusions:

    • The CCR score is a significant prognostic tool across various risk groups and management strategies in localized prostate cancer.
    • CCR's prognostic value is maintained after adjusting for initial management and clinicopathologic factors.
    • CCR effectively supplements conventional risk models, enhancing clinical decision-making.